



PrEP Uptake and Utilisation Among Adolescent Girls and Young Women in Sub-Saharan Africa: A Scoping Review

Jenny Chen-Charles^{1,2} · Dvora Joseph Davey^{3,4} · Elona Toska^{2,5} · Janet Seeley^{6,7,8} · Linda-Gail Bekker¹

Accepted: 4 February 2025
© The Author(s) 2025

Abstract

Adolescent girls and young women (AGYW) in sub-Saharan Africa (SSA) are disproportionately affected by HIV. Despite the effectiveness of oral pre-exposure prophylaxis (PrEP) in preventing HIV, uptake and effective utilisation among AGYW remain suboptimal. This scoping review maps research on PrEP delivery outside clinical trials to AGYW in SSA. Quantitative and qualitative data were extracted from 58 studies on the facilitators and barriers to PrEP uptake and utilisation (including initiation, persistence, and adherence), and recommendations for effective PrEP delivery from AGYW and PrEP providers. Only studies on oral PrEP met the inclusion criteria. Facilitators of effective PrEP utilisation included social support with strong familial and peer networks positively influencing PrEP adherence and persistence. Healthcare provider interactions were pivotal in promoting PrEP uptake through dissemination of accurate information and ongoing support. Studies reported consistent barriers to PrEP uptake and utilisation including anticipated or experienced stigma, pill burden, and side effects. Addressing identified barriers and leveraging facilitators can enhance future effectiveness for PrEP delivery. There is a lack of strategies to support AGYW in long-term persistence and engagement with PrEP services. Our findings emphasise the urgent need for people-centred and localised, context-specific strategies to improve PrEP delivery among AGYW in SSA. Effective PrEP delivery strategies should include differentiated service delivery models, innovative approaches such as digital health, and integration with existing services such as antenatal care for pregnant and breastfeeding AGYW. More data is needed for PrEP delivery among AGYW across the region, including other PrEP modalities as they roll out.

Keywords PrEP · Adolescent girls and young women (AGYW) · Service delivery · Sub-Saharan Africa · Facilitators to PrEP · Barriers to PrEP · HIV prevention

Background

Globally, 3800 adolescent girls and young women (AGYW) acquired HIV every week in 2023, with 76% of those infections occurring in sub-Saharan Africa (SSA) [1]. In 2023, 198,000 AGYW (15–24 years old) were reported to have newly acquired HIV in SSA and were three times more likely to acquire HIV than their male counterparts [1]. This disproportionate burden of HIV among AGYW in the region may be due to a variety of biological, social, and structural factors, including gender-based violence, limited access to health services—including sexual and reproductive health (SRH) services, and socioeconomic vulnerabilities [2–4]. These statistics highlight the urgent need for comprehensive prevention programs tailored for AGYW.

✉ Jenny Chen-Charles
jenny.chen1@alumni.lshtm.ac.uk

- ¹ Desmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa
- ² Department of Social Policy and Intervention, University of Oxford, Oxford, UK
- ³ Department of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa
- ⁴ Division of Infectious Diseases, Geffen School of Medicine, University of California, Los Angeles, CA, USA
- ⁵ Centre for Social Science Research, University of Cape Town, Rondebosch, South Africa
- ⁶ Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa
- ⁷ School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

- ⁸ Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK

Effective daily oral pre-exposure prophylaxis (PrEP) use can provide robust protection against HIV acquisition across all populations, reducing the chances of HIV acquisition to almost zero [5]. In 2015, WHO recommended PrEP for AGYW in high HIV burden areas, expanding in 2021 to include the dapivirine vaginal ring and in 2022 the Cabotegravir Long-Acting (CAB-LA) injections for individuals at risk of exposure [6]. More recently, the twice-yearly Lenacapavir injections have shown high efficacy in clinical trials, with no reported HIV infections among women in the PURPOSE-1 study [7]. However, the effectiveness of these methods relies on uptake and effective utilisation (uninterrupted use prior to time of exposure) as PrEP is a user-controlled HIV prevention method [8]. Women, including AGYW, in Africa have particularly reported challenges with PrEP adherence and persistence [9–13].

By 2024, approximately 6.7 million individuals globally had at least one use of oral PrEP administration, with a large contribution from South Africa, having surpassed 1.3 million oral PrEP initiations [14, 15]. Additionally, 144 nations have incorporated the WHO's guidelines on oral PrEP into their national policies, with another 14 countries planning to implement these recommendations within the next two years [16]. However, effective PrEP uptake and utilisation is far from reaching the 2025 target, and access in low- and middle-income countries is still limited [1, 17]. Inequality in access is also clear within countries that have adopted the WHO PrEP recommendations and have widespread PrEP availability [18]. Many low- and middle-income countries rely on international donor-funded programmes to provide access to services and resources, suggesting significant variability in PrEP access both between and within countries [19, 20].

Given this context, we aimed to review existing publications around PrEP delivery among AGYW in SSA to identify barriers, facilitators, and recommendations for effective PrEP uptake and utilisation among AGYW in SSA. By doing so, we seek to inform tailored and effective interventions to improve PrEP uptake and adherence in this high-incidence population.

Methods

A scoping review was conducted to assess the size and scope of existing literature on PrEP uptake and utilisation among AGYW in SSA, given the broad and varied nature of the available studies [21]. The PRISMA framework for conducting scoping reviews was used to guide this review (see Table 1 for the population, concept and context, and see Supplementary Appendix 1 for detailed steps taken) [22]. This review included both quantitative and qualitative evidence, therefore mixed methods research syntheses following Joanna Briggs

Table 1 Population, concept, and context for the review

Population

The population included in this study were adolescent girls and young women (ages 10–24 years)

Concept

Real-world PrEP roll-out and delivery

Context

This review considered studies from sub-Saharan Africa

Institute (JBI)'s convergent segregated approach was used to synthesise and present the findings. Quantitative and qualitative findings, including from mixed methods studies, were first analysed separately followed by convergence of the findings (see Supplementary Appendix 2) [23].


Data Sources and Search Strategy

We systematically searched relevant peer-reviewed literature using search terms related to PrEP, AGYW, delivery and implementation, and names of all SSA countries (see Supplementary Appendix 3 for the search terms). Databases searched include PubMed and Ovid (including Embase, MEDLINE, Scopus, Global Health, PsycInfo). Publications were limited to records that were published after 2012, when PrEP was first approved for use by the US Food and Drug Administration (FDA) [24]. Email notifications were configured for Ovid to alert about new records uploaded to the database from the initial search in June 2022 until the end of February 2024. Additionally, PubMed was periodically searched with a final search conducted at the end of February 2024.

Inclusion and Exclusion Criteria

As this review focused on real-world evidence on PrEP delivery, only research that reported empirical evidence was included. Studies that reported on the different stages of the PrEP cascade, i.e. on the following outcomes: PrEP initiation (or uptake—defined as an individual starting on PrEP), PrEP persistence (or retention, continuation—defined as the duration an individual continues to take PrEP as prescribed, without interruption), PrEP adherence (which can be measured through various methods, including pharmacological measures of drug levels in the body, pill counts, or self-reported adherence over a reference period, as defined by the authors of each study), and PrEP re-initiation following discontinuation; and the facilitators and barriers to the PrEP cascade outcomes were included. Studies that presented perspectives from both the supply side (i.e. PrEP providers) and demand side (i.e. AGYW) were included. Any studies on clinical trials, or those that only reported on hypothetical

Fig. 1 Adapted socioecological framework for HIV prevention among adolescents (adapted from [26])



willingness or acceptability of PrEP were excluded from this review. Studies that did not have age-disaggregated data for 10–24-year olds were also excluded.

Data Extraction and Synthesis

Articles were screened using EPPI Reviewer [25]. The first author screened all title and abstracts to remove irrelevant search results using pre-specified screening questions to determine if they met the inclusion criteria. Full texts of the selected studies were then retrieved and screened for inclusion. A second reviewer (DJD) independently screened a random selection of 10% of title and abstracts, and then 10% of studies included for full-text screening to ensure accuracy. Interrater reliability was assessed using two measures: Cohen's Kappa coefficient (0.77), which indicates substantial agreement beyond chance, and the proportion of studies with consistencies between raters (94%), reflecting excellent agreement. Any inconsistencies (6% of studies) were reconciled through discussion and consensus.

Data were systematically extracted using a pre-developed data extraction sheet. Quantitative and qualitative syntheses were undertaken separately (also including data from mixed methods studies in both streams). Evidence derived from both syntheses was then merged using an adapted socioecological framework specifically tailored for HIV prevention among adolescents. This framework captures the dynamic and multifaceted nature of individual experiences, recognising that influences on adolescents are not static but are instead complex, fluid, and shaped by their interactions across individual, social/sexual network/family, community, and healthcare provider/logistical-level factors (see Fig. 1)

[26]. Recommendations from AGYW and PrEP implementors were also extracted and synthesised.

During the review, it was found that the terms PrEP 'persistence', 'continuation', and 'retention' were used interchangeably across different quantitative studies, and their measurements varied from one study to another. We have used the term persistence in this review, but this also includes reports of continuation and retention. More salient findings on facilitators and barriers (those that were reported by three or more studies) are presented in the results section, but all findings can be found in the mapping tables (see Tables 2, 3). When findings were exclusively qualitative or quantitative, this was indicated in the results section. Otherwise, findings were synthesised and merged from both types of data.

Results

Out of 877 studies identified following database search and deduplication, 58 studies were eligible for inclusion (see Fig. 2 for the PRISMA flowchart). More than half (55%) of the studies used qualitative methods, 38% used quantitative, and 7% used mixed methods. Most studies were conducted in South Africa (44%) and Kenya (38%), with the rest conducted in Uganda (6%), Zimbabwe (4%), Eswatini (3%), Zambia (1%), Namibia (1%), and Tanzania (1%). Only studies on oral PrEP met the inclusion criteria for real-world delivery; studies on other PrEP modalities including injectable PrEP did not meet the inclusion criteria due to the novelty of these methods.

Table 2 Facilitators of PrEP uptake and utilisation among AGYW in SSA identified from studies synthesised by socioecological level

Socioecological level	Facilitator	Qualitative references	Country	Quantitative references	Country
Individual-level Facilitators	AGYW knowledge and awareness of PrEP and its benefits	Rousseau et al. [53]	South Africa	Joseph Davey et al. [30]	South Africa
		Mudzingwa et al. [54]	South Africa		
		Jackson-Gibson et al. [55]	Kenya		
		Rogers et al. [56]	Kenya		
		Kawuma et al. [57]	Uganda		
		de Vos et al. [58]	South Africa		
		Barnighausen et al. [59]	Eswatini		
		Joshi et al. [60]	Uganda	Truong et al. [45]	Kenya
		Mudzingwa et al. [61]	South Africa	Martin et al. [46]	South Africa
		Rousseau et al. [53]	South Africa	Rao et al. [43]	South Africa
	Understanding personal risk for HIV acquisition, and increased HIV-related knowledge	Jackson-Gibson et al. [55]	Kenya	Khadka et al. [40]	South Africa
		de Vos et al. [58]	South Africa		
		Bhattacharjee et al. [50]	Kenya		
		Ngure et al. [62]	Kenya		
		Jani et al. [63]	Tanzania	Pintye et al. [42]	Kenya
		Joshi et al. [60]	Uganda	Bonner et al. [39]	Kenya
		Rousseau et al. [53]	South Africa		
		Barnighausen et al. [59]	Eswatini		
		Rogers et al. [56]	Kenya		
		Pintye et al. [65]	Kenya		
	Self-efficacy and internal motivation—PrEP use fostering sense of agency and self-care	Joseph Davey et al. [67]	South Africa		
		Skovdal et al. [66]	Zimbabwe		
		Barnighausen et al. [59]	Eswatini		
		Jani et al. [63]	Tanzania		
		Joshi et al. [60]	Uganda		
		Rousseau et al. [72]	South Africa		
	Motherhood and pregnancy- desire to protect their child's future and maintain their own health for their children's sake				
	PrEP fosters a sense of agency and self-care – contributing to positive shifts in relationship dynamics and behaviour				

Table 2 (continued)

Socioecological level	Facilitator	Qualitative references	Country	Quantitative references	Country
Social/Sexual Network/Family-level Facilitators	Autonomy in healthcare decision-making and ability to take PrEP discreetly	Rousseau et al. [53]	South Africa		
		Wyatt et al. [64]	South Africa		
	Positive response to disclosure of PrEP use within their social, sexual and family networks	Jackson-Gibson et al. [55]	Kenya		
		Pintye et al. [65]	Kenya		
		Barnighausen et al. [59]	Eswatini		
		Joshi et al. [60]	Uganda	Zia et al. [44]	Kenya
		Mudzingwa et al. [61]	South Africa		
		Rousseau et al. [53]	South Africa		
		Mudzingwa et al. [54]	South Africa		
		Katz et al. [68]	Kenya, South Africa		
	Ability to have transparent communication with partners regarding PrEP use—importance of partner education, and continued communication with partners regarding PrEP use	Wyatt et al. [64]	South Africa	Bonner et al. [39]	Kenya
		Jackson-Gibson et al. [55]	Kenya	Tapsoba et al. [37]	Kenya
Community-level Facilitators	Parental guidance and support in sexual and reproductive health decisions—providing informational and instrumental support	Ndimande-Khoza et al. [72]	South Africa	Truong et al. [45]	Kenya
		Wong et al. [71]	Zambia	Joseph Davey et al. [30]	South Africa
	Ongoing family and social support networks help them to cope with challenges—including tangible support in the form of encouragement and reminders	Beesham et al. [69]	South Africa	Truong et al. [45]	Kenya
		Ndimande-Khoza et al. [70]	Kenya, South Africa	Joseph Davey et al. [30]	South Africa
		Pintye et al. [65]	Kenya	Mudau et al. [33]	South Africa
		Chimbindi et al. [49]	South Africa	Zia et al. [44]	Kenya
	Positive community attitudes towards PrEP—importance of engagement with stakeholders	Barnabee et al. [52]	Namibia		
		de Vos et al. [58]	South Africa		
	Community-based outreach and education programmes led by communities themselves	Jackson-Gibson et al. [55]	Kenya	Joseph Davey et al. [30]	South Africa
		Chimbindi et al. [49]	South Africa	Tapsoba et al. [37]	Kenya
				Mayanja et al. [32]	Uganda
				Butler et al. [47]	South Africa
				Tapsoba [37]	Kenya

Table 2 (continued)

Socioecological level	Facilitator	Qualitative references	Country	Quantitative references	Country
Healthcare Provider-level and Structural Facilitators	Provision of safe spaces for education and engagement for PrEP	Jackson-Gibson et al. [55]	Kenya		
	Participation in peer support groups	Cassidy et al. [48]	South Africa	Joseph Davey et al. [30]	South Africa
	Peer-led outreach approaches	Bhattacharjee et al. [50] Chimbindi et al. [49]	Kenya South Africa		
	Peers who continue to use PrEP			Zia et al. [44]	Kenya
	Effective education campaigns informing AGYW of PrEP benefits	Cassidy et al. [48]	South Africa		
	Integration of PrEP education at antenatal care clinics	Joseph Davey et al. [67]	South Africa		
	Adolescent-friendly, non-judgemental, and supportive counselling that provides comprehensive information, address concerns, and prepare AGYW for potential challenges	Beesham et al. [69] Joseph Davey et al. [67] Katz et al. [68]	South Africa South Africa Kenya, South Africa	Martin et al. [46] Zia et al. [44]	South Africa Kenya
	Friendly and welcoming clinic staff who offer support, information, and reassurance about PrEP	Ngure et al. [62]	Kenya		
		Bhattacharjee et al. [50]	Kenya		
		Rousseau et al. [72]	South Africa		
		Beesham et al. [69]	South Africa		
	Logistical facilitators including integration of PrEP into existing health services, support for accessing clinics for PrEP refills, free transportation services, reduced stigma associated with PrEP dispensing	Rousseau et al. [72]	South Africa		
		Vera et al. [73]	Kenya		
		Rogers et al. [56]	Kenya	Khadka et al. [40]	South Africa
		Rousseau et al. [53] Cassidy et al. [48] Chimbindi et al. [49]	South Africa South Africa South Africa		
	Consistent supply and access to PrEP at clinics	Bhattacharjee et al. [50] Vera et al. [73]	Kenya Kenya		
				Mayanja et al. [32] Rao et al. [43]	Uganda South Africa

Table 2 (continued)

Socioecological level	Facilitator	Qualitative references	Country	Quantitative references	Country
				Butler et al. [47]	South Africa
				Zia et al. [44]	Kenya
	Adequate training for healthcare providers, coupled with non-judgmental and supportive services			Butler et al. [47]	South Africa
				Zia et al. [44]	Kenya
	Provision of affordable or complimentary PrEP services to alleviate financial barriers			Mudau et al. [33]	South Africa
				Zia et al. [44]	Kenya
	Effective programme monitoring	Bhattacharjee et al. [50]	Kenya		
	Community and hybrid service delivery models	Barnabee et al. [52]	Namibia		
	Pharmacy delivery of PrEP—enhances accessibility and convenience	Vera et al. [73]			Kenya
	Flexible clinic hours and appointment scheduling			Mayanja et al. [32]	Uganda

Table 3 Barriers of PrEP uptake and utilisation among AGYW identified from studies synthesised by socioecological level

Socioecological level	Barriers	Qualitative references	Country	Quantitative references	Country
Individual-level Barriers	Stigma and misconceptions among families, peers, communities—leading to challenges including the need to conceal PrEP use	Beesham et al. [74]	South Africa	Zia et al. [44]	Kenya
		Wagner et al. [75]	Kenya	Mayanja et al. [32]	Uganda
		Mudzingwa et al. [61]	South Africa	Tapsoba et al. [37]	Kenya
		Rousseau et al. [72]	South Africa		
		Wyatt et al. [64]	South Africa		
		Escudero et al. [76]	Kenya		
		Skovdal et al. [78]	Zimbabwe		
		Beesham et al. [69]	South Africa		
		Jani et al. [63]	Tanzania		
		Joshi et al. [60]	Uganda		
		Perry et al. [77]	Kenya		
		Vera et al. [73]	Kenya		
		Ndimande-Khoza et al. [70]	Kenya, South Africa		
		de Vos et al. [58]	South Africa		
		Cassidy et al. [48]	South Africa		
		Chimbindi et al. [49]	South Africa		
		Bhattacharjee et al. [50]	Kenya		
	Disclosure-related factors—including discouraging and negative reactions, the need for family approval, or family prohibition	Barnabee et al. [52]	Namibia		
		Mudzingwa et al. [54]	South Africa		
		Beesham et al. [74]	South Africa		
		Mudzingwa et al. [61]	South Africa		
		Rousseau et al. [53]	South Africa		
		Skovdal et al. [84]	Zimbabwe		
		Joshi et al. [60]	Uganda		
		Perry et al. [77]	Kenya		
		Ndimande-Khoza et al. [70]	Kenya, South Africa		
		Beesham et al. [74]	South Africa	Celum et al. [28]	Kenya, South Africa
	Side-effects: anticipated/fear of or actual experiences—including gastrointestinal discomfort and headaches	Duby et al. [79]	South Africa	Mudau et al. [33]	South Africa

Table 3 (continued)

Socioecological level	Barriers	Qualitative references	Country	Quantitative references	Country
Socioecological level	Pill fatigue/burden, and other factors related to pill-taking such as the size of the pill	Jackson-Gibson et al. [55]	Kenya	Bonner et al. [39]	South Africa
		Rogers et al. [56]	Kenya	Pintye et al. [42]	Kenya
		Rousseau et al. [72]	South Africa		
		Wyatt et al. [64]	South Africa		
		Escudero et al. [76]	Kenya		
		de Vos et al. [58]	South Africa		
		Chimbindi et al. [49]	South Africa		
		Barnabee et al. [52]	Namibia		
		Mudzingwa et al. [54]	South Africa		
		Beesham et al. [74]	South Africa	Bonner et al. [39]	South Africa
		Perry et al. [77]	Kenya	Pintye et al. [42]	Kenya
		Rousseau et al. [72]	South Africa		
		Duby et al. [79]	Africa		
		Bjertrup et al. [80]	Eswatini		
Socioecological level	Pregnancy and breastfeeding-related fears of harmful effects on their foetus or infants	de Vos et al. [58]	South Africa		
		Kawuma et al. [57]	Uganda		
		Joshi et al. [60]	Uganda		
		Wyatt et al. [64]	South Africa		
		Rogers et al. [56]	Kenya		
		Pintye et al. [65]	Kenya		
		Wyatt et al. [64]	South Africa		
		Beesham et al. [74]	South Africa		
		Pintye et al. [65]	Kenya		
		Duby et al. [79]	South Africa	Kinuthia et al. [31]	Kenya
		Rousseau et al. [53]	South Africa	Giovenco et al. [29]	South Africa, Zimbabwe
		Escudero et al. [76]	Kenya		
		de Vos et al. [58]	South Africa		
		Perry et al. [77]	Kenya		
		Mudzingwa et al. [61]	South Africa	Haberer et al. [51]	Kenya
Socioecological level	Low or lowered perception of HIV risk	Perry et al. [77]	Kenya	Sila et al. [36]	Kenya

Socioecological level

Socioecological level	Barriers	Qualitative references	Country	Quantitative references	Country
Social/Sexual Network/Family-level Barriers	Mobile lifestyles or frequent relocation, and being away from home when PrEP needed to be taken lead to forgetfulness or changes in routine which triggered missed doses	Rousseau et al. [72]	South Africa	Martin et al. [46]	South Africa
		de Vos et al. [58]	South Africa	Ogolla et al. [41]	Kenya
		Beesham et al. [74]	South Africa		
		Beesham et al. [69]	South Africa		
	Other life priorities, scheduling conflicts, and difficulties in accessing PrEP	Jackson-Gibson et al. [55]	Kenya		
		Pintye et al. [65]	Kenya		
		de Vos et al. [58]	South Africa		
		Chimbindi et al. [49]	South Africa		
	Clinic-related anxiety due to negative experiences with healthcare providers, and concerns around being judged at clinics. Clinics perceived as not youth-friendly and overworked	Wyatt et al. [64]	South Africa		
		Beesham et al. [74]	South Africa		
		Mudzingwa et al. [61]	South Africa		
		Perry et al. [77]	Kenya		
	Decreased motivation and/or capacity to engage with PrEP services due to experiencing depressive symptoms and intimate partner violence	de Vos et al. [58]	South Africa		
		Rousseau et al. [72]	South Africa		
		Escudero et al. [76]	Kenya		
		Omollo et al. [85]	Kenya		
	Lack of internal motivation to take PrEP			Bonner et al. [39]	South Africa
				Martin et al. [46]	South Africa
				Heck et al. [38]	Kenya
		Rousseau et al. [72]	South Africa		
	Reluctance to retest for HIV due to emotional stress and logistical barriers	Pintye et al. [65]	Kenya		
		Escudero et al. [76]	Kenya		
	Partner influence—negative reactions from male partners, viewing PrEP use as sign of mistrust or infidelity leading to relationship discord, and partners sharing inaccurate information about PrEP	Bjertrup et al. [80]	Eswatini	Butler et al. [47]	South Africa
		Jani et al. [63]	Tanzania	Pintye et al. [42]	Kenya
		Katz et al. [68]	Kenya, South Africa		
		Rogers et al. [56]	Kenya		
		Skovdal et al. [78]	Zimbabwe		
		de Vos et al. [58]	South Africa		
		Pintye et al. [65]	Kenya		

Table 3 (continued)

Socioecological level	Barriers	Qualitative references	Country	Quantitative references	Country
Community-level Barriers	Fear of partner—partner prohibitions/disapproval or anticipated conflict caused by PrEP use, experiences of intimate partner violence (IPV)	Barnighausen et al. [59]	Eswatini	Ohiomoba et al. [35]	Kenya
		Holmes et al. [81]	South Africa	Rao et al. [43]	South Africa
		Mudzingwa et al. [61]	South Africa		
		Perry et al. [77]	Kenya		
	Parental resistance and family disapproval, misinformation, and parents feeling poorly consulted or informed	Rousseau et al. [72]	South Africa		
		Bjertrup et al. [80]	Eswatini	Joseph Davey et al. [30]	South Africa
		Duby et al. [79]	South Africa	Ohiomoba et al. [35]	Kenya
		Bhattacharjee et al. [50]	Kenya		
	Stigma associated with HIV and PrEP usage within social environments, and negative social influences or absence of supportive networks	Ndimande-Khoza et al. [70]	Kenya, South Africa	Truong et al. [45]	Kenya
		Duby et al. [79]	South Africa	Zia et al. [44]	Kenya
	Community stigma and misconceptions	Duby et al. [79]	South Africa	Butler et al. [47]	South Africa
		Jackson-Gibson et al. [55]	Kenya	Tapsoba et al. [37]	Kenya
	Resistance from religious leaders	Lanham et al. [82]	Kenya		
		Wong et al. [71]	Zambia		
		Duby et al. [79]	South Africa		
		Katz et al. [68]	Kenya, South Africa		
Healthcare Provider-level and Structural Barriers	Patriarchal and social norms	Perry et al. [77]	Kenya		
		Skovdal et al. [84]	Zimbabwe		
	Resource allocation and perceived workload and burden of incorporating PrEP services into existing workflows	Barnighausen et al. [59]	Eswatini		
		Jackson-Gibson et al. [55]	Kenya		
		Skovdal et al. [84]	Zimbabwe		
		Chimbindi et al. [49]	South Africa		
		Bhattacharjee et al. [50]	Kenya		
		Barnabee et al. [52]	Namibia		
		O'Malley et al. [83]	Kenya, South Africa		

Table 3 (continued)

Socioecological level	Barriers	Qualitative references	Country	Quantitative references	Country
Lack of training and knowledge among HCPs—concerns among HCPs about PrEP's safety and efficacy, particularly during pregnancy and breastfeeding, and drug resistance and sexual behaviours of AGYW which leads to reluctance to provide PrEP services		O'Malley et al. [83]	Kenya, South Africa	Bonner et al. [39]	South Africa
		Chimbindi et al. [49] Perry et al. [77]	South Africa Kenya	Mudau et al. [33]	South Africa
Logistical barriers—particularly in rural areas due to distance from services, protracted waiting times, screening requirements, and restricted clinic hours		Beesham et al. [69]	South Africa	Martin et al. [46]	South Africa
		Joshi et al. [60]	Uganda	Mayanja et al. [32]	Uganda
		Pintye et al. [65]	Kenya	Butler et al. [47]	South Africa
		de Vos et al. [58]	South Africa	Rao et al. [43]	South Africa
		Vera et al. [73]	Kenya		
Service disruptions due to health facility closures, inadequate stock management and stockouts, and inadequate follow-up and support from HCPs, as well as disruptions caused by COVID-19 which exacerbated these challenges		Beesham et al. [69]	South Africa	Ogolla et al. [41]	Kenya
		Duby et al. [79]	South Africa	Rao et al. [43]	South Africa
				Mayanja et al. [32]	Uganda
				Butler et al. [47]	South Africa
				Khadka et al. [40]	South Africa
Financial constraints and absence of affordable PrEP options		Beesham et al. [74]			South Africa
				Ogolla et al. [41] Rao et al. [43]	Kenya South Africa




Fig. 2 PRISMA flowchart for article selection. T&A screening = title and abstract screening

Quantitative Findings on PrEP Initiation, Persistence, and Adherence

The synthesis of data from $n = 22$ quantitative studies and $n = 3$ mixed methods studies conducted in South Africa, Kenya, Zimbabwe and Uganda showed large variations in proportions of PrEP initiation among eligible HIV-negative AGYW, ranging from 2 to 82% (measured by 24 studies) [27–50]. But it was clear across the studies that PrEP persistence decreased when measured across time, e.g. 3-months, 6-months and/or 12-months, with persistence rates ranging from 29 to 58% after 3-months (measured by 17 studies) [28, 30–35, 37, 39–43, 48, 50–52]. Only three studies measured PrEP adherence, with the majority (67%) of participants having consistently low adherence [48], adherence declining over time and demonstrably low adherence when measured at month 6 (18%) [29], and month 22 (15%) [51].

Merged Qualitative and Quantitative Findings

Facilitators for PrEP Uptake and Utilisation

Individual-Level Facilitators Qualitative findings from studies in four SSA countries revealed that a positive perception of PrEP as an effective HIV prevention method significantly motivated AGYW to initiate and adhere to PrEP [53–59]. Quantitative data indicated that adequate knowledge and awareness about PrEP encouraged initiation [30].

Findings from studies in Kenya, South Africa, and Uganda showed that AGYW's understanding of their personal risk for HIV acquisition was a crucial motivator for PrEP uptake. Qualitative and quantitative studies emphasised that recognising their greater likelihood of exposure to HIV drove AGYW to use PrEP [40, 43, 45, 46, 53, 55, 58, 60–62]. Additionally, the persistent perception of HIV risk motivated AGYW to continue using PrEP [43, 46], or to re-initiate [45, 46].

Findings from studies in five SSA countries underscored the significant role of self-efficacy and internal motivation. Qualitative findings from studies in Eswatini, Kenya, and South Africa highlighted that PrEP use fostered a sense of agency and self-care and contributed to a sense of relief and hope for the future, as well as positive shifts in relationship dynamics and risk behaviour [53, 59, 60, 63]. The importance of AGYW's autonomy in healthcare decision-making and their ability to take PrEP discreetly was essential [53, 55, 59, 64, 65]. Quantitative data from Kenya confirmed that higher levels of self-efficacy and internal motivation were associated with increased PrEP initiation and persistence [39, 42].

Motherhood or pregnancy emerged as strong motivators for PrEP use in qualitative studies from Kenya, South Africa, and Zimbabwe. The desire to protect their child's future and maintain their own health for their children's sake drove AGYW to initiate and adhere to PrEP [40, 56, 65–67].

Social/Sexual Network/Family-Level Facilitators The synthesis of qualitative and quantitative findings underscored the pivotal role of positive social, sexual, and family networks in facilitating effective PrEP uptake, persistence and adherence among AGYW. Qualitative data from Kenya and South Africa noted that positive responses to PrEP use disclosure within these networks significantly empowered AGYW to make informed decisions about their health and well-being, and use PrEP [53, 54, 60, 61, 68]. Quantitative findings from a study in Kenya supported this, indicating that support from peers, partners, or healthcare providers played a role in encouraging individuals to re-engage and resume PrEP use [44].

Qualitative studies from South Africa and Kenya highlighted the importance of educating male sexual partners about PrEP, which not only encouraged their partners' participation but also strengthened relationship dynamics [55, 64]. Quantitative data showed that continued communication with partners regarding PrEP use enhanced persistence among AGYW [37, 39].

Ongoing family and social support and approval, including tangible support such as encouragement and reminders, also played a role in facilitating PrEP initiation and maintenance by fostering a supportive environment for PrEP adherence and persistence [49, 52, 58, 65, 69, 70]. Qualitative

findings from studies in Zambia and South Africa emphasised the role of parental guidance and support in daughters' SRH decisions, particularly in providing informational and instrumental support such as guidance on dealing with side effects and accompaniment to clinics [30, 45, 70, 71].

Community-Level Facilitators Findings from studies in Kenya, South Africa, and Uganda highlighted the significant role of positive community attitudes towards PrEP, which significantly mitigated stigma and enhanced uptake among AGYW. The engagement of community stakeholders helped address misconceptions and resistance and promoted a positive perception of PrEP within the community for AGYW [30, 37, 55]. For example, a study in Kenya showed engagement and collaborations with the Kenyan Ministry of Health and key opinion leaders was important in overcoming initial barriers to PrEP implementation and ensuring successful PrEP delivery to AGYW [55].

Healthcare Provider-Level and Structural Facilitators The successful uptake and continued use of PrEP by AGYW was significantly influenced by several healthcare provider-level and logistical facilitators. Qualitative findings from studies in Kenya and South Africa emphasised the importance of adolescent-friendly, non-judgmental, and supportive counselling, including counselling services integrated into Antenatal Care (ANC) and Postnatal Care (PNC) services. Counsellors played a role in facilitating PrEP acceptance by providing comprehensive information, addressing concerns, and preparing AGYW for potential challenges associated with PrEP use [44, 46, 50, 62, 67–69, 72].

Studies from South Africa and Kenya reported how the attitude and demeanour of healthcare providers also significantly impacted PrEP uptake. Friendly and welcoming clinic staff who offered support, information, and reassurance regarding PrEP and its potential side effects helped alleviate AGYW's concerns and promoted continued engagement with PrEP services [69, 72, 73]. Additional logistical support for access to clinics for PrEP refills such as free transportation services, reduced stigma associated with PrEP dispensing, and integration of PrEP into existing healthcare systems enhanced convenience and accessibility and ensured AGYW could easily initiate and persist on PrEP services [40, 48–50, 56, 72, 73].

Barriers to PrEP Uptake and Utilisation

Individual-Level Barriers The synthesis of qualitative and quantitative findings identified several significant individual-level barriers to the uptake and consistent use of PrEP among AGYW. The most salient barrier reported by studies in five SSA countries was anticipated or experienced stigma and misconceptions about PrEP among families, peers, and

communities of AGYW, including confusion of PrEP with antiretroviral therapy (ART) for HIV treatment. This created considerable challenges for PrEP persistence and adherence due to the reported need to conceal PrEP use, which exacerbated challenges with keeping PrEP schedules and missing doses, and eventually lead to discontinuation [48–50, 52, 54, 58, 60, 61, 63, 64, 66, 69, 70, 72–77]. Issues related to disclosure of PrEP use, such as discouraging and negative reactions, the need for family or partner approval, and family prohibition reported in studies from four SSA countries also made consistent PrEP use challenging [53, 60, 61, 70, 74, 77, 78]. Lack of knowledge and misconceptions about PrEP, worsened by misinformation from online sources, such as negative rumours about PrEP's safety and side effects, was reported in studies from Kenya, South Africa and Zimbabwe, and contributed to AGYW's resistance to PrEP uptake and discontinuation [29, 31, 53, 58, 76, 77, 79].

Fear and the actual experience of side effects, including gastrointestinal discomfort and headaches, were well documented in studies from South Africa and Kenya, and acted as a deterrent for PrEP initiation and retention [28, 33, 39, 42, 49, 52–56, 58, 64, 74, 76, 79]. Furthermore, issues related to pill fatigue, pill burden, and the physical size of the pill which made swallowing the pill difficult also discouraged AGYW from consistent PrEP use in studies from four SSA countries [39, 42, 53, 57, 58, 74, 77, 79, 80]. Pregnant and breastfeeding AGYW in studies from Kenya, South Africa and Uganda also feared any harmful effects PrEP might have on their foetus or infants, or future fertility, and cited higher percentage of gastrointestinal side effects, which negatively impacted their uptake and use of PrEP [40, 56, 60, 64, 65].

Furthermore, low perceived risk of HIV acquisition emerged as a significant barrier in studies from South Africa and Kenya, including qualitative studies which illustrated how changes in relationship status or condom use contributed to a diminished perception of HIV risk, and led to PrEP discontinuation [36, 41, 46, 51, 53, 58, 61, 77]. Additionally, mobile lifestyles, frequent relocations, and being away from home interfered with a consistent PrEP regimen [49, 55, 58, 64, 65, 69, 74]. Other life priorities (such as work or school), scheduling conflicts, and difficulties in accessing PrEP distribution sites also impeded consistent use [53, 58, 61, 74, 77]. AGYW with mental health issues, which was often associated with stigma, discrimination, social isolation, and intimate partner violence (IPV), faced challenges in persistent PrEP use [38, 39, 46].

Social/Sexual Network/Family-Level Barriers Quantitative and qualitative evidence from studies in five SSA countries underscored the highly influential role of male partners in AGYW's PrEP decisions. Negative reactions, opposition, perception of PrEP as a sign of mistrust or infidelity, lack of support, or inaccurate information about PrEP from male

partners significantly undermined AGYW's motivation to initiate or persist in PrEP use [42, 47, 56, 58, 63, 65, 66, 68, 80]. In addition, experiences of IPV, fear of partners, and concerns about relationship instability further hindered PrEP uptake and persistence [35, 43, 59, 61, 72, 77, 81].

Studies in Eswatini, Kenya, and South Africa showed parental opposition, fuelled by misconceptions about PrEP (such as mistaking it for ART or abortion pills), complicated AGYW's access to accurate information and support, subsequently negatively impacted PrEP uptake [30, 35, 45, 50, 70, 79, 80].

Community-Level Barriers Studies in four SSA countries emphasised that community stigma, misconceptions, and disapproval—often fuelled by a lack of awareness and the incorrect belief that PrEP promotes risky sexual behaviour—created a hostile environment and significantly hindered PrEP uptake and use [37, 47, 55, 71, 79, 82]. Religious opposition, rooted in the perception that PrEP promotion conflicted with religious values, and patriarchal norms and beliefs in conservative communities reinforced negative community perceptions around PrEP and created additional barriers [68, 77–79].

Healthcare Provider-Level and Structural Barriers Studies from five SSA countries highlighted the challenges related to resource allocation and the perceived workload and burden by healthcare providers of incorporating PrEP services into existing workflows. Qualitative findings indicated that limited financial and human resources restricted the time healthcare providers could spend with AGYW, impacting the timely availability of PrEP services and counselling, which consequently reduced AGYW's motivation to continue PrEP [49, 50, 52, 55, 59, 78, 83]. A lack of training and knowledge or negative attitudes among healthcare providers, concerns about PrEP's safety and efficacy, particularly during pregnancy and breastfeeding, and reluctance to provide PrEP services due to worries about drug resistance and sexual behaviours of AGYW hindered PrEP initiations [33, 39, 49, 77, 83].

Studies from Kenya, South Africa and Uganda highlighted structural issues such as limited and unreliable transport, financial difficulties, long waiting times at clinics, restricted clinic opening hours, and screening requirements as deterrents for PrEP uptake and access among AGYW [32, 43, 46, 47, 58, 60, 65, 69, 73]. Inadequate stock management and frequent stockouts at healthcare facilities limited the availability of PrEP and impeded initiation [32, 40, 41, 43, 47, 69, 74, 79]. Postpartum women who no longer attended ANC's faced additional difficulties accessing PrEP appointments or picking up refills [64, 65, 74].

AGYW and PrEP Provider Recommendations for PrEP Delivery from Qualitative Studies

PrEP providers and AGYW in qualitative studies recommended various strategies to improve PrEP uptake, adherence, and persistence among AGYW. Both PrEP providers and AGYW emphasised the importance of community leader involvement for sensitisation, promotion, and implementation of PrEP initiatives, alongside reaching AGYW within educational settings to disseminate PrEP knowledge [59, 84]. Collaboration between community-based implementers and clinic staff was highlighted as crucial for promoting PrEP uptake through referrals [79]. Raising awareness about PrEP through community campaigns and discussions was recommended to address stigma and normalise its usage, alongside dispelling misconceptions about PrEP's association with increased sexual activity and promiscuity [79, 82–84]. AGYW specifically suggested integrating PrEP delivery into existing healthcare services such as ANC's and informing their social networks about PrEP benefits to reduce stigma and misconceptions [67–69]. They also emphasised on the need for PrEP advocacy through peers, recommended couple PrEP counselling and comprehensive PrEP education for male partners, and improved parent–child communication on SRH topics to foster mutual support and understanding [53, 54, 63, 71, 77].

Parental engagement and fostering open communication and support through trustful relationships was considered crucial by both AGYW and PrEP providers for supporting AGYW's effective use of PrEP [79, 82]. Encouraging couples' HIV testing and counselling was also recommended to enhance PrEP uptake [82]. Intensified counselling, tailored to AGYW's unique circumstances and needs, was suggested to address adherence and persistence challenges, with a conversational approach during PrEP counselling appreciated by AGYW [82, 83, 85]. Improving patient-centred care, ensuring privacy, and providing non-judgmental treatment are key components of youth-friendly services. This also requires sensitisation and training programmes for healthcare workers, community health workers, and peer educators. [76, 83–85]. Offering discreet options for administering PrEP could address concerns about stigma, while tangible support through tracking missed client visits and providing follow-up through calls, SMS, and home visits could promote persistence [82, 84]. AGYW also suggested ensuring suitable clinic hours, integrating queues to pick up PrEP at health facilities, and providing reliable transportation assistance [69, 77]. Discreet administration options and expanding PrEP service locations to community settings and schools were suggested to address disclosure and storage issues [53, 69, 72].

Leveraging social media platforms was recommended by both AGYW and PrEP providers to facilitate reaching AGYW with PrEP-related information, encouraging them to

reflect on their HIV risk and empowering them to take charge of their health [82, 85]. Utilising peer educators and implementing demand creation activities could increase PrEP awareness [84]. Reimbursing transport costs and exploring alternative delivery points beyond HIV treatment clinics could improve accessibility to PrEP services, while involving key opinion leaders, including adolescents, in policymaking could ensure effective and sustainable PrEP implementation [76].

Discussion

We synthesised evidence on PrEP delivery to AGYW in SSA in this review, highlighting multifaceted challenges in real-world PrEP delivery and underscoring poor PrEP uptake and persistence due to barriers at various socioecological levels. The geographic focus on South Africa and Kenya emphasises the need for more comprehensive studies across SSA. Variability in PrEP initiation, influenced by factors such as location and HIV prevalence, underpins the necessity for localised and context-specific strategies [86, 87].

Significant gaps exist at each stage of the PrEP cascade – stigma, misinformation, and structural challenges hinder PrEP awareness, access, and initiation. Social support, healthcare provider interactions, and structural barriers affect PrEP adherence and persistence. There is a notable lack of strategies that support AGYW in long-term persistence and keeping them engaged in PrEP services. Interventions should address specific barriers and facilitators for AGYW at each stage of the PrEP cascade. This includes understanding the role of continuous PrEP education and engagement with AGYW, their social networks, and their communities for effective implementation. Differentiated Service Delivery (DSD) models have shown effectiveness for ART delivery and retention, such as through adherence clubs and community ART groups – these strategies could also be adopted for PrEP services to address similar issues in adherence [88, 89].

The need for improved PrEP delivery mechanisms and addressing accessibility issues surrounding costs and distance to clinics suggest the necessity for policy interventions. Alternative PrEP delivery mechanisms, such as mobile clinics and pharmacies, nurse-led models, and community-based approaches, should be explored to promote equitable access. These strategies have already shown effectiveness in other populations, and in contraceptive delivery. For example, a systematic review on PrEP uptake among female sex workers in SSA found community-based models, including pharmacies, significantly improved retention rates [90]. Trained community health workers showed success in the delivery of injectable contraceptives in SSA communities [91]. Peer- and

community-led HIV responses also demonstrated improvements in HIV service access, utilisation, linkage, retention, and quality [92].

Innovative, people-focused approaches are essential to improving PrEP access and adherence. These might include virtual consultations and support systems for adherence, mobile health units to reach remote populations, and the use of community-based PrEP ambassadors [93]. Research from Kenya has indicated that AI-driven telehealth platforms could significantly alleviate the pressure on healthcare providers and systems in resource-limited settings [94]. Furthermore, more practical solutions to help AGYW conceal PrEP and navigate stigma is needed, such as changing the design of the pills or the containers to prevent confusion with ART [84, 95, 96].

This review also emphasises the importance of community-centric approaches – to involve not only healthcare providers but also community leaders, parents, and peers in promoting and normalising PrEP use. Social, religious, and cultural barriers continue to create significant barriers to PrEP uptake, especially since cultural and religious norms that oppose the use of preventive measures such as PrEP may deter AGYW from seeking care [68, 78, 79]. In some contexts, PrEP use may be linked to promiscuity, conflicting with gender or religious norms [78]. These perceptions can cause AGYW to hesitate in seeking SRH services and PrEP, due to fear of social exclusion or familial rejection. To overcome this, interventions must be culturally sensitive, involving community and religious leaders and incorporating relevant education into HIV prevention programmes to foster support for PrEP and improve SRH outcomes for AGYW. For example, community-supported models of care, such as for ART delivery and condom distribution, have shown effectiveness in reducing HIV stigma and increasing condom use [97].

Pregnancy and motherhood also emerged as strong motivators for PrEP use, with AGYW driven by the desire to protect their children's future and maintain their own health [98–100]. This highlights the need for more research focusing on AGYW mothers, as understanding their unique motivations and barriers can inform the design of tailored interventions that address the specific needs of this population with additional vulnerabilities. Integrating services in family planning (FP), SRH services, and ANC is crucial to ensure comprehensive support for AGYW and especially those who are pregnant, breastfeeding, and mothers. Such integration can enhance access to PrEP and other essential health services, contributing to better health outcomes for both mothers and their children. Integration of SRH and HIV services is recommended by the WHO, as it would improve access, quality of ANCs, and healthcare provider productivity [101]. This approach could also help reduce stigma and structural barriers for AGYW. A systematic review on

integrating FP and HIV testing services also found that integrating services improved uptake, service quality, client satisfaction, whilst reducing stigma and structural barriers [102].

Incorporating recommendations from AGYW and PrEP providers is overdue; their role in shaping PrEP strategies is essential. Insights from AGYW ensure a thorough understanding of their unique needs, preferences, and challenges related to effective PrEP uptake and utilisation. Input from PrEP providers ensure practical feasibility and alignment with clinical practices, addressing not only the practical aspects of PrEP delivery but also the societal and interpersonal factors that influence its acceptance and utilisation. This collaborative approach helps develop evidence-based interventions that are also culturally sensitive.

Strengths and Limitations

This review comprehensively captured existing evidence on real-world PrEP delivery by including both quantitative and qualitative studies. It specifically extracted data on facilitators and barriers to PrEP uptake and utilisation across the socioecological levels. However, the exclusion of grey literature due to its lack of peer review, and conference abstracts may have resulted in missing relevant data. The focus on real-world PrEP delivery meant only studies on oral PrEP were included, as studies on emerging new PrEP modalities such as injectable PrEP did not meet the inclusion criteria.

However, identified studies are valuable for informing the implementation of new PrEP modalities that are being made available, such as the vaginal ring and injectable PrEP methods. We urgently need to design tailored strategies, including tailored education, community engagement, and healthcare provider training for new PrEP modalities as they begin to roll out. Therefore, while findings in this review are rooted in oral PrEP delivery, this review provides a foundational framework for enhancing the uptake, persistence and adherence of new PrEP modalities among AGYW in SSA.

Conclusion

In this scoping review we mapped the complexities surrounding PrEP uptake and utilisation among AGYW in SSA. We found significant barriers at each stage of the PrEP cascade, and a notable lack of strategies to support AGYW in long-term persistence and engagement with PrEP services. However, we also identified key facilitators that, if strengthened, could improve PrEP uptake and long-term engagement. Future strategies for PrEP delivery should not only focus on overcoming barriers but also on strengthening the facilitators that encourage uptake and persistence. Every day, AGYW in SSA face the risk of HIV acquisition, and there is the

opportunity to prevent these new HIV cases through effective PrEP delivery and supporting effective utilisation as part of comprehensive HIV prevention packages. Policymakers, researchers, and stakeholders must act now to address the barriers to PrEP uptake and utilisation including stigma, negative sexual/family/social network influences, and structural barriers. Effective strategies for PrEP delivery need to be implemented, which could include DSD models, innovative approaches such as telehealth, and integrating PrEP with existing services. Understanding the unique needs of AGYW mothers and addressing their specific barriers can further inform tailored interventions for this particularly affected population. Long acting PrEP modalities, which could help address barriers, need to be made widely available to bring us closer to the goal of an HIV-free generation.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10461-025-04656-4>.

Funding Open access funding provided by University of Cape Town. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Supervision provided by Elona Toska was funded by the UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1); the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434 (the content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health); and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (n° 771468).

Declarations

Conflict of Interest There are no conflicts of interest.

Ethical Approval Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. UNAIDS. The urgency of now: AIDS at a crossroads—2024 global AIDS update. Geneva; 2024.
2. Gium T, Wasie A, Lenti K, Muktar E, Shumbej T, Difer M, et al. Gender disparity in epidemiological trend of HIV/AIDS

- infection and treatment in Ethiopia. Arch Public Health [Internet]. 2018;76(1):1–10. <https://doi.org/10.1186/s13690-018-0299-8>.
3. Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis [Internet]. 2014;209(suppl_3):S86–92. <https://doi.org/10.1093/infdis/jiu175>.
4. Magadi MA. Understanding the gender disparity in HIV infection across countries in sub-Saharan Africa: evidence from the Demographic and Health Surveys. Sociol Health Illn [Internet]. 2011;33(4):522–39. <https://doi.org/10.1111/j.1467-9566.2010.01304.x>.
5. O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open [Internet]. 2022;12(5):e048478. <https://bmjopen.bmj.com/content/12/5/e048478>
6. WHO. Global HIV Programme—Pre-exposure prophylaxis (PrEP) [Internet]. <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis>.
7. Bekker LG, Das M, Abdoool Karim Q, Ahmed K, Bating J, Brumskine W, et al. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. New England Journal of Medicine [Internet]. (2024). <https://doi.org/10.1056/NEJMoa2407001>
8. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep [Internet]. 2011;8(1):62–72. <https://pubmed.ncbi.nlm.nih.gov/20941553/>.
9. Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc [Internet]. (2020). <https://pubmed.ncbi.nlm.nih.gov/33247553/>.
10. Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Health [Internet]. 2020;4(12):875–83. <https://pubmed.ncbi.nlm.nih.gov/33222803/>.
11. Fonner VA, Dalglisch SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS [Internet]. 2016;30(12):1973–83. <https://pubmed.ncbi.nlm.nih.gov/27149090/>.
12. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodini N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med [Internet]. 2015;372(6):509–18. <https://pubmed.ncbi.nlm.nih.gov/25651245/>.
13. Irungu EM, Baeten JM. PrEP rollout in Africa: status and opportunity [Internet]. Vol. 26, Nature Medicine. Nature Research; 2020. p. 655–64. <https://doi.org/10.1038/s41591-020-0872-x>
14. AVAC. PxWire. Volume 14, Issue No. 1. A quarterly update on HIV prevention research; February 29 2024. <https://avac.org/resource/report/pxwire-feb2024/>
15. AVAC. AVAC: The global PrEP tracker [Internet]; 2024. <https://data.prepwatch.org/>.
16. WHO. Global state of PrEP [Internet]. <https://www.who.int/groups/global-prep-network/global-state-of-prep>.
17. UNAIDS. HIV prevention 2025 road map—Getting on track to end AIDS as a public health threat by 2030 | UNAIDS [Internet]. Geneva; 2022. <https://www.unaids.org/en/resources/documents/2022/prevention-2025-roadmap>.
18. Bavinton BR, Grulich AE. HIV pre-exposure prophylaxis: scaling up for impact now and in the future. Lancet Public Health [Internet]. 2021;6(7):e528–33. <http://www.thelancet.com/article/S2468266721001122/fulltext>.
19. Lagarde M, Palmer N. The impact of health financing strategies on access to health services in low and middle income countries. Cochrane Database Syst Rev [Internet]. 2018. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6494435/>.
20. Resch S, Hecht R. Transitioning financial responsibility for health programs from external donors to developing countries: Key issues and recommendations for policy and research. J Glob Health [Internet]. 2018. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5782833/>
21. Grant MJ, Booth A. Research Guides: Reviewing Research: Literature Reviews, Scoping Reviews, Systematic Reviews: Differentiating the Three Review Types. Health Info Libr J [Internet]. 2009;26(2):91–108. <https://research.lib.buffalo.edu/literature-scoping-systematicreviews/introduction>.
22. Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol [Internet]. 2016. <https://bmcmmedresmethodol.biomedcentral.com/articles/10.1186/s12874-016-0116-4>
23. Stern C, Lizarondo L, Carrier J, Godfrey C, Rieger K, Salmond S, et al. Methodological guidance for the conduct of mixed methods systematic reviews. JBI Evid Synth [Internet]. 2020;18(10):2108–18. https://journals.lww.com/jbisrir/fulltext/2020/10000/methodological_guidance_for_the_conduct_of_mixed.3.aspx.
24. Roehr B. FDA approves first drug to prevent HIV infection. BMJ [Internet]. 2012;345. <https://www.bmj.com/content/345/bmj.e4879>.
25. Thomas JBJGS. EPPI-reviewer 40: software for research synthesis. EPPI centre software. London: Social Science Research Unit, Institute of Education, University of London; 2010.
26. Pettifor A, Stoner M, Pike C, Bekker LG. Adolescent lives matter: preventing HIV in adolescents. Curr Opin HIV AIDS [Internet]. 2018;13(3):265. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5902132/>
27. Atkins K, Rucinski K, Mudavanhu M, Holmes L, Mutunga L, Kaufman MR, et al. Sexual relationship types, partner HIV self-testing, and pre-exposure prophylaxis among South African adolescent girls and Young Women: a latent class analysis. J Acquir Immune Defic Syndr [Internet]. 2021;86(4):413–21. <https://pubmed.ncbi.nlm.nih.gov/33196552/>
28. Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, et al. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/35822945/>.
29. Giovenco D, Pettifor A, Powers KA, Hightow-Weidman L, Pence BW, Celum C, et al. Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women. AIDS [Internet]. 2022;36(8):1151–9. <https://pubmed.ncbi.nlm.nih.gov/35579012/>.
30. Joseph Davey DL, Mvududu R, Mashele N, Lesosky M, Khadka N, Bekker LG, et al. Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa. J Int AIDS Soc [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/35138678/>.
31. Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV [Internet]. 2020;7(1):e38–48. <https://pubmed.ncbi.nlm.nih.gov/31813837/>.

32. Mayanja Y, Kamacooko O, Lunkuse JF, Muturi-Kioi V, Buzibye A, Omali D, et al. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study. *J Int AIDS Soc* [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/35543110/>.
33. Mudau DO, Mulaudzi FM, Sepeng N V., Anokwuru R. Assessing HIV Pre-exposure Prophylaxis Uptake and Retention Amongst Young Females in Gauteng Province. *AIDS Behav* [Internet]. 2023;27(4):1182–7. <https://pubmed.ncbi.nlm.nih.gov/36166108/>.
34. Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. *PLoS Med* [Internet]. 2019. <https://pubmed.ncbi.nlm.nih.gov/31479452/>.
35. Ohiomoba RO, Owuor PM, Orero W, Were I, Sawo F, Ezema A, et al. Pre-Exposure Prophylaxis (PrEP) Initiation and Retention Among Young Kenyan Women. *AIDS Behav* [Internet]. 2022;26(7):2376–86. <https://pubmed.ncbi.nlm.nih.gov/35061115/>.
36. Sila J, Larsen AM, Kinuthia J, Owiti G, Abuna F, Kohler PK, et al. High Awareness, Yet Low Uptake, of Pre-Exposure Prophylaxis Among Adolescent Girls and Young Women Within Family Planning Clinics in Kenya. *AIDS Patient Care STDS* [Internet]. 2020;34(8):336. <https://pubmed.ncbi.nlm.nih.gov/32757980/>.
37. Tapsoba JD, Cover J, Obong'o C, Brady M, Cressey TR, Mori K, et al. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study. *PLoS Med* [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/36095005/>.
38. Heck CJ, Mathur S, Alwang'a H, Daniel OM, Obanda R, Owiti M, et al. Oral PrEP consultations among adolescent girls and young women in Kisumu County, Kenya: Insights from the DREAMS Program. *AIDS Behav* [Internet]. 2022;26(8):2516. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9252953/>.
39. Bonner CP, Minnis AM, Ndirangu JW, Browne FA, Speizer I, Nyblade L, et al. The importance of the individual in PrEP uptake: multilevel correlates of PrEP uptake among adolescent girls and young women in Tshwane, South Africa. *AIDS Behav* [Internet]. 2023;27(12):4124–30. <https://pubmed.ncbi.nlm.nih.gov/37439915/>.
40. Khadka N, Gorbach PM, Nyemba DC, Mvududu R, Mashele N, Javanbakht M, et al. Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa. *Front Reprod Health* [Internet]. 2023. <https://pubmed.ncbi.nlm.nih.gov/37795521/>.
41. Ogolla M, Nyabiage OL, Musingila P, Gachau S, Odero TMA, Odoyo-June E, et al. Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya. *J Int AIDS Soc* [Internet]. 2023;26(3):26069. <https://pubmed.ncbi.nlm.nih.gov/36912204/>.
42. Pintye J, Odoyo J, Nyerere B, Achieng P, Araka E, Omondi C, et al. Nurse-facilitated preexposure prophylaxis delivery for adolescent girls and young women seeking contraception at retail pharmacies in Kisumu, Kenya. *AIDS* [Internet]. 2023;37(4):617. <https://pubmed.ncbi.nlm.nih.gov/36653342/>.
43. Rao A, Lesko C, Mhlophe H, Rucinski K, McInzana M, Pretorius A, et al. Longitudinal patterns of initiation, persistence, and cycling on PrEP among female sex workers and adolescent girls and young women in South Africa, 2016–2021. *AIDS* [Internet]. 2023;37(6):977. <https://pubmed.ncbi.nlm.nih.gov/36723509/>.
44. Zia Y, Etyang L, Nyerere B, Nyamwaro C, Mogaka F, Mwangi M, et al. Structural influences on delivery and use of oral HIV PrEP among adolescent girls and young women seeking post abortion care in Kenya. *EClinicalMedicine* [Internet]. 2024. <https://pubmed.ncbi.nlm.nih.gov/38292038/>.
45. Truong HHM, Heylen E, Kadede K, Amboka S, Otieno B, Odhiambo H, et al. Brief Report: HIV Pre-Exposure Prophylaxis Awareness and Use Among Adolescents in Kenya. *J Acquir Immune Defic Syndr* [Internet]. 2024;95(2):133–7. <https://pubmed.ncbi.nlm.nih.gov/37988676/>.
46. Martin CE, Cox LA, Nongena P, Butler V, Ncube S, Sawry S, et al. Patterns of HIV Pre-exposure Prophylaxis use Among Adolescent Girls and Young Women Accessing Routine Sexual and Reproductive Health services in South Africa. *J Adolesc Health* [Internet]. 2023;73(6S):S81–91. <https://pubmed.ncbi.nlm.nih.gov/37953014/>.
47. Butler V, Kutwayo A, Martin CE, Pleaner M, Mojapele M V., Ncube S, et al. Implementing Differentiated and Integrated HIV Prevention Services for Adolescent Girls and Young Women: Experiences From Oral PrEP Rollout in Primary Care Services in South Africa. *J Adolesc Health* [Internet]. 2023;73(6S):S58–66. <https://pubmed.ncbi.nlm.nih.gov/37953010/>.
48. Cassidy T, Ntuli N, Kilani C, Malabi N, Rorwana B, Mutseykwa T, et al. Delivering PrEP to Young Women in a Low-Income Setting in South Africa: Lessons for Providing Both Convenience and Support. *AIDS Behav* [Internet]. 2022;26(1):147–59. <https://pubmed.ncbi.nlm.nih.gov/34259963/>.
49. Chimbindi N, Mthiyane N, Zuma T, Baisley K, Pillay D, McGrath N, et al. Antiretroviral therapy based HIV prevention targeting young women who sell sex: a mixed method approach to understand the implementation of PrEP in a rural area of KwaZulu-Natal, South Africa. *AIDS Care* [Internet]. 2022;34(2):232. <https://pubmed.ncbi.nlm.nih.gov/33769156/>.
50. Bhattacharjee P, Musau A, Manguro G, Ongwen P, Mutegi J, Kioko J, et al. HIV prevention programme with young women who sell sex in Mombasa, Kenya: learnings for scale-up. *J Int AIDS Soc* [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/36028893/>.
51. Haberer JE, Mugo N, Bukusi EA, Ngure K, Kiptinness C, Oware K, et al. Understanding pre-exposure prophylaxis adherence in young women in Kenya. *J Acquir Immune Defic Syndr* [Internet]. 2022;89(3):251–60. <https://pubmed.ncbi.nlm.nih.gov/35147580/>.
52. Barnabee G, O'Bryan G, Ndeikemona L, Billah I, Silas L, Morgan KL, et al. Improving HIV pre-exposure prophylaxis persistence among adolescent girls and young women: insights from a mixed-methods evaluation of community, hybrid, and facility service delivery models in Namibia. *Frontiers in reproductive health* [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/36545490/>.
53. Rousseau E, Katz AWK, O'Rourke S, Bekker LG, Delany-Moretlwe S, Bukusi E, et al. Adolescent girls and young women's PrEP-user journey during an implementation science study in South Africa and Kenya. *PLoS One* [Internet]. 2021. <https://pubmed.ncbi.nlm.nih.gov/34648589/>.
54. Krogstad Mudzingwa E, de Vos L, Atujuna M, Fynn L, Mugore M, Mabandla S, et al. High study participation but diverging adherence levels: qualitatively unpacking PrEP use among adolescent girls and young women over two years in Eastern Cape, South Africa. *J Behav Med* [Internet]. 2024;47(2):320–33. <https://pubmed.ncbi.nlm.nih.gov/38081955/>.
55. Jackson-Gibson M, Ezema AU, Orero W, Were I, Ohiomoba RO, Mbullo PO, et al. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya. *BMC Public Health* [Internet]. 2021;21(1):1–13. <https://doi.org/10.1186/s12889-021-11335-1>

56. Rogers Z, Pintye J, Kinuthia J, O'Malley G, Abuna F, Escudero J, et al. Key influences on the decision to initiate PrEP among adolescent girls and young women within routine maternal child health and family planning clinics in Western Kenya. *AIDS Care* [Internet]. 2022;34(3):363–70. <https://doi.org/10.1080/09540121.2021.1981217>.
57. Kawuma R, Nabalwanyi Z, Seeley J, Mayanja Y. “I prefer to take pills when I plan to have sex”: Perceptions of on-demand versus daily oral pre-exposure prophylaxis among adolescents in Kampala, Uganda. *Afr J AIDS Res* [Internet]. 2022;21(1):8–14. <https://pubmed.ncbi.nlm.nih.gov/35361065/>
58. de Vos L, Mudzingwa EK, Fynn L, Atujuna M, Mugore M, Gandhi M, et al. Factors that influence adolescent girls and young women's re-initiation or complete discontinuation from daily oral PrEP use: a qualitative study from Eastern Cape Province, South Africa. *J Int AIDS Soc* [Internet]. 2023;26(9):e26175. <https://doi.org/10.1002/jia2.26175>.
59. Bärnighausen K, Matse S, Hughey AB, Hettema A, Bärnighausen TW, McMahon SA. “We know this will be hard at the beginning, but better in the long term”: understanding PrEP uptake in the general population in Eswatini. *AIDS Care* [Internet]. 2020;32(2):267–73. <https://pubmed.ncbi.nlm.nih.gov/31437021/>
60. Joshi S, Namuddu C, Kasujja FX, Mirembe M, Homsy J, Seeley J, et al. PrEP uptake and persistence amongst HIV-negative women who exchange sex for money or commodities in Kampala, Uganda: a qualitative inquiry assessing the influence of pregnancy. *PLoS Glob Public Health* [Internet]. 2023;3(6):e0000434. <https://pubmed.ncbi.nlm.nih.gov/37368866/>
61. Mudzingwa EK, de Vos L, Atujuna M, Fynn L, Mugore M, Hosek S, et al. Factors influencing adolescent girls and young women's uptake of community-based PrEP services following home-based HIV testing in Eastern Cape, South Africa: a qualitative study. *AIDS Behav* [Internet]. 2022;26(11):3726–39. <https://pubmed.ncbi.nlm.nih.gov/35653046/>
62. Ngure K, Thuo N, Ogello V, Kiptinness C, Kamolloh K, Burns BFOR, et al. Dynamic perceived HIV risk and sexual behaviors among young women enrolled in a PrEP Trial in Kenya: a qualitative study. *Front Reproduct Health* [Internet]. 2021;3:637869. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9580724/>
63. Jani N, Mathur S, Kahabuka C, Makyao N, Pilgrim N. Relationship dynamics and anticipated stigma: key considerations for PrEP use among Tanzanian adolescent girls and young women and male partners. *PLoS One* [Internet]. 2021. <https://pubmed.ncbi.nlm.nih.gov/33596216/>
64. Wyatt MA, Pisarski EE, Kriel Y, Smith PM, Mathenjwa M, Jaggermath M, et al. Influences on PrEP uptake and adherence among South African women during periconception and pregnancy: a qualitative analysis. *AIDS Behav* [Internet]. 2023;27(1):208–17. <https://pubmed.ncbi.nlm.nih.gov/35771311/>
65. Pintye J, O'Malley G, Kinuthia J, Abuna F, Escudero JN, Mugambi M, et al. Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation From a PrEP implementation program. *J Acquir Immune Defic Syndr* [Internet]. 2021;86(4):E83–9. <https://pubmed.ncbi.nlm.nih.gov/33273211/>
66. Skovdal M, Magoge-Mandizvidza P, Dzatatira F, Maswera R, Nyamukapa C, Thomas R, et al. Improving access to pre-exposure prophylaxis for adolescent girls and young women: recommendations from healthcare providers in eastern Zimbabwe. *BMC Infect Dis* [Internet]. 2022;22(1):1–10. <https://doi.org/10.1186/s12879-022-07376-5>.
67. Joseph Davey DL, Knight L, Markt-Maloney J, Tsawe N, Gomba Y, Mashele N, et al. “I had Made the Decision, and No One was Going to Stop Me”—facilitators of PrEP adherence during pregnancy and postpartum in Cape Town, South Africa. *AIDS Behav* [Internet]. 2021;25(12):3978–86. <https://pubmed.ncbi.nlm.nih.gov/34085132/>
68. Katz AWK, Roberts S, Rousseau E, Khoza MN, Mogaka F, Bukusi E, et al. Qualitative analysis using social maps to explore young women's experiences with social support of their oral PrEP use in Kenya and South Africa. *J Assoc Nurses AIDS Care* [Internet]. 2023;34(1):45–57. <https://pubmed.ncbi.nlm.nih.gov/36170124/>
69. Beesham I, Milford C, Smit J, Joseph Davey DL, Baeten JM, Heffron R, et al. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa. *BMC Public Health* [Internet]. 2023. <https://pubmed.ncbi.nlm.nih.gov/37349816/>
70. Ndimande-Khoza MN, Katz AWK, Moretlwe-Delany S, Travill D, Rousseau E, Omollo V, et al. Family influences on oral PrEP use among adolescent girls and young women in Kenya and South Africa. *PLoS One* [Internet]. 2023;18(11):e0292529. <https://doi.org/10.1371/journal.pone.0292529>
71. Wong CM, Munthali T, Mangunje FG, Katoka ML, Burke HM, Musonda B, et al. Creating allies: qualitative exploration of young women's preferences for PrEP methods and parents' role in PrEP uptake and user support in urban and rural Zambia. *BMC Womens Health* [Internet]. 2024;24(1):1–10. <https://doi.org/10.1186/s12905-024-02913-7>
72. Rousseau E, Bekker LG, Julies RF, Celum C, Morton J, Johnson R, et al. A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa. *BMC Health Serv Res* [Internet]. 2021;21(1):1–10. <https://doi.org/10.1186/s12913-021-06920-4>
73. Vera M, Bukusi E, Achieng P, Aketch H, Araka E, Baeten JM, et al. “Pharmacies are Everywhere, and You can get it at any Time”: experiences with pharmacy-based prep delivery among adolescent girls and young women in Kisumu, Kenya. *J Int Assoc Provid AIDS Care* [Internet]. 2023. <https://pubmed.ncbi.nlm.nih.gov/37997351/>
74. Beesham I, Dovel K, Mashele N, Bekker LG, Gorbach P, Coates TJ, et al. Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence among pregnant and post-partum women from Cape Town, South Africa. *AIDS Behav* [Internet]. 2022;26(9):3079. <https://pubmed.ncbi.nlm.nih.gov/35316471/>
75. Wagner AD, Beima-Sofie K, Awuor M, Owade W, Neary J, Dettinger JC, et al. Implementation determinants and strategies in integration of PrEP into maternal and child health and family planning services: experiences of frontline healthcare workers in Kenya. *Front Reproduct Health* [Internet]. 2023. <https://pubmed.ncbi.nlm.nih.gov/37799494/>
76. Escudero JN, Dettinger JC, Pintye J, Kinuthia J, Lagat H, Abuna F, et al. Community perceptions about use of pre-exposure prophylaxis among adolescent girls and young women in Kenya. *J Assoc Nurses AIDS Care* [Internet]. 2020;31(6):669–77. <https://pubmed.ncbi.nlm.nih.gov/32675642/>
77. Perry B, Molokwu N, Agot K, Ngoje DO, Strack R, Corneli A. Multilevel factors influencing interruptions in PrEP use among young women in Siaya County, Kenya. *AIDS Educ Prev* [Internet]. 2023;35(2):141–57. <https://pubmed.ncbi.nlm.nih.gov/37129591/>
78. Skovdal M, Clausen CL, Magoge-Mandizvidza P, Dzatatira F, Maswera R, Nyamwanza RP, et al. How gender norms and ‘good girl’ notions prevent adolescent girls and young women from engaging with PrEP: qualitative insights from Zimbabwe. *BMC Womens Health* [Internet]. 2022;22(1):1–10. <https://doi.org/10.1186/s12905-022-01928-2>
79. Duby Z, Bunce B, Fowler C, Jonas K, Bergh K, Govindasamy D, et al. “These Girls Have a Chance to be the Future Generation of HIV Negative”: Experiences of implementing a PrEP programme for adolescent girls and young Women in South Africa. *AIDS Behav* [Internet]. 2023;27(1):134. <https://pubmed.ncbi.nlm.nih.gov/35793053/>

80. Bjertrup PJ, Mmemma N, Dlamini V, Ciglenecki I, Mpala Q, Matse S, et al. PrEP reminds me that I am the one to take responsibility of my life: a qualitative study exploring experiences of and attitudes towards pre-exposure prophylaxis use by women in Eswatini. *BMC Public Health* [Internet]. 2021;21(1):1–8. <https://doi.org/10.1186/s12889-021-10766-0>.
81. Holmes LE, Kaufman MR, Casella A, Mudavanhu M, Mutunga L, Polzer T, et al. Qualitative characterizations of relationships among South African adolescent girls and young women and male partners: implications for engagement across HIV self-testing and pre-exposure prophylaxis prevention cascades. *J Int AIDS Soc* [Internet]. 2020;23(S3): e25521. <https://doi.org/10.1002/jia2.25521>.
82. Lanham M, Ridgeway K, Mireku M, Nhamo D, Pillay D, Murire M, et al. Health care providers' attitudes toward and experiences delivering oral PrEP to adolescent girls and young women in Kenya, South Africa, and Zimbabwe. *BMC Health Serv Res* [Internet]. 2021;21(1):1–12. <https://doi.org/10.1186/s12913-021-06978-0>.
83. O'Malley G, Beima-Sofie KM, Roche SD, Rousseau E, Travill D, Omollo V, et al. Health care providers as agents of change: integrating PrEP with other sexual and reproductive health services for adolescent girls and young women. *Front Reproduct Health* [Internet]. 2021;3:668672. <https://pubmed.ncbi.nlm.nih.gov/36303982/>
84. Skovdal M, Magoge-Mandizvidza P, Dzatatira F, Maswera R, Nyamukapa C, Thomas R, et al. Improving access to pre-exposure prophylaxis for adolescent girls and young women: recommendations from healthcare providers in eastern Zimbabwe. *BMC Infect Dis* [Internet]. 2022;22(1):1–10. <https://doi.org/10.1186/s12879-022-07376-5>
85. Omollo V, Roche SD, Mogaka F, Odoyo J, Barnabee G, Bukusi EA, et al. Provider-client rapport in pre-exposure prophylaxis delivery: a qualitative analysis of provider and client experiences of an implementation science project in Kenya. *Sex Reprod Health Matters* [Internet]. 2022. <https://pubmed.ncbi.nlm.nih.gov/36169648/>
86. World Health Organization. Consolidated guidelines on HIV prevention, testing, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021; p. 592.
87. World Health Organization. Guidance for national strategic planning (NSP): Health sector response to HIV, viral hepatitis and sexually transmitted infections [Internet]. Geneva; 2023. <https://www.who.int/publications/book-orders>.
88. IAS—The International AIDS Society. Facilitating effective transitions between differentiated service delivery models for HIV treatment. 2023. <https://www.differentiatedservicedelivery.org>
89. Bwire GM, Njiro BJ, Ndumwa HP, Munishi CG, Mpondo BC, Mganga M, et al. Impact of differentiated service delivery models on retention in HIV care and viral suppression among people living with HIV in sub-Saharan Africa: A systematic review and meta-analysis of randomised controlled trials. *Rev Med Virol* [Internet]. 2023. <https://pubmed.ncbi.nlm.nih.gov/37655428/>
90. Mpirirwe R, Segawa I, Ojiambo KO, Kamacooko O, Nangendo J, Semitala FC, et al. HIV pre-exposure prophylaxis uptake, retention and adherence among female sex workers in sub-Saharan Africa: a systematic review. *BMJ Open* [Internet]. 2024;14(4):e076545. <https://bmjopen.bmj.com/content/14/4/e076545>
91. Ayuk BE, Yankam BM, Saah FI, Bain LE. Provision of injectable contraceptives by community health workers in sub-Saharan Africa: a systematic review of safety, acceptability and effectiveness. *Hum Resour Health* [Internet]. 2022;20(1):1–14. <https://doi.org/10.1186/s12960-022-00763-8>
92. Ayala G, Sprague L, Leigh-Ann van der Merwe L, Thomas RM, Chang J, Arreola S, et al. Peer- and community-led responses to HIV: a scoping review. *PLoS One* [Internet]. 2021;16(12):e0260555. <https://doi.org/10.1371/journal.pone.0260555>
93. UNAIDS and WHO. Innovate, Implement, Integrate: Virtual interventions in response to HIV, sexually transmitted infections and viral hepatitis. 2022. <https://wearesocial.com/digital-2021>
94. Mendonca R, Rech D, Frade S, Morris S, Smedinghoff S, Ibrahim A, et al. Improving confidence and trust in private-sector telemedicine for HIV PrEP/PEP delivery with AI. In: *AIDS 2024*. Munich: IAS; 2024.
95. Stoebeu K, Muchanga G, Ahmad SSO, Bwalya C, Mwale M, Toussaint S, et al. Barriers and facilitators to uptake and persistence on prep among key populations in Southern Province, Zambia: a thematic analysis. *BMC Public Health* [Internet]. 2024;24(1):1–16. <https://doi.org/10.1186/s12889-024-19152-y>.
96. Muhumuza R, Ssemata AS, Kakande A, Ahmed N, Atujuna M, Nomvuyo M, et al. Exploring perceived barriers and facilitators of PrEP uptake among young people in Uganda, Zimbabwe, and South Africa. *Arch Sex Behav* [Internet]. 2021;50(4):1729–42. <https://doi.org/10.1007/s10508-020-01880-y>.
97. Ibiyoye O, Masquillier C, Jwanle P, Van Belle S, van Olmen J, Lynen L, et al. Community-based ART service delivery for key populations in Sub-Saharan Africa: scoping review of outcomes along the continuum of HIV care. *AIDS Behav* [Internet]. 2022;26(7):2314–37. <https://doi.org/10.1007/s10461-021-03568-3>.
98. Davey DLJ, Mvududu R, Mashele N, Lesosky M, Khadka N, More J, et al. Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa. *medRxiv* [Internet]. 2021. <https://doi.org/10.1101/2021.05.04.21256514v1>
99. Joseph Davey DL, Bekker LG, Gorbach PM, Coates TJ, Myer L. Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier. *AIDS* [Internet]. 2017;31(16):2193–7. <https://pubmed.ncbi.nlm.nih.gov/28723709/>
100. Moran A, Mashele N, Mvududu R, Gorbach P, Bekker LG, Coates TJ, et al. Maternal PrEP use in HIV-uninfected pregnant women in South Africa: role of stigma in PrEP initiation, retention and adherence. *AIDS Behav* [Internet]. 2022;26(1):205–17. <https://doi.org/10.1007/s10461-021-03374-x>.
101. Ford N, Newman M, Malumo S, Chitembo L, Gaffield ME. Integrating sexual and reproductive health services within HIV services: WHO Guidance. *Front Glob Womens Health* [Internet]. 2021;2:735281. <https://www.frontiersin.org>
102. Narasimhan M, Yeh PT, Haberlen S, Warren CE, Kennedy CE. Integration of HIV testing services into family planning services: a systematic review. *Reprod Health* [Internet]. 2019;16(1):1–12. <https://doi.org/10.1186/s12978-019-0714-9>.